Phase II Study of V-BEAM Conditioning Regimen Prior to Second Autologous Stem Cell Transplantation

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Washington University School of Medicine
ClinicalTrials.gov Identifier:
NCT01653418
First received: July 23, 2012
Last updated: January 31, 2014
Last verified: January 2014

July 23, 2012
January 31, 2014
September 2012
August 2013   (final data collection date for primary outcome measure)
Complete response rate (complete response + stringent complete response) at Day +100 as defined by the International Myeloma Working Group (IMWG) criteria [ Time Frame: Day +100 ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01653418 on ClinicalTrials.gov Archive Site
  • Progression-free survival (PFS) [ Time Frame: 3 months following Day +100 visit ] [ Designated as safety issue: No ]
    Every 3 months
  • Overall response rate (ORR) [ Time Frame: 3 months following Day +100 visit ] [ Designated as safety issue: No ]
    ORR includes Minimal Response (MR) + Partial Response (PR) + Very Good Partial Response (VGPR) + Near Complete Response (nCR) + Stringent Complete Response (sCR) + Complete Response (CR)
  • Percentage of patients achieving at least very good partial response rate (VGPR+nCR+sCR+CR) [ Time Frame: Day +100 ] [ Designated as safety issue: No ]
  • Toxicity of V-BEAM [ Time Frame: 30 days after end of treatment / Day +100 ] [ Designated as safety issue: Yes ]
    Patients are evaluated from first receiving study treatment until a 30-day follow-up after the conclusion of treatment for adverse events not resulting in death. Adverse events resulting in death will be evaluated through Day +100.
  • Time to neutrophil engraftment after V-BEAM. [ Time Frame: Day +100 ] [ Designated as safety issue: Yes ]
    Time to neutrophil engraftment is defined as duration between Day 0 to the first day of ANC > 0.5x109/L post transplant when it is sustained for more than three consecutive days.
  • Overall survival (OS) [ Time Frame: 3 months following Day +100 visit ] [ Designated as safety issue: No ]
  • Treatment related mortality (TRM) of V-BEAM [ Time Frame: Day +100 ] [ Designated as safety issue: Yes ]
  • Time to platelet engraftment after V-BEAM. [ Time Frame: Day +100 ] [ Designated as safety issue: Yes ]
    Time to platelet engraftment is defined as the duration between Day 0 to the first day of platelet count sustained at > 20x109/L without transfusion. The median time to neutrophil and platelet engraftment will be reported.
  • Progression-free survival (PFS) [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • Overall response rate (ORR) [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    ORR includes Minimal Response (MR) + Partial Response (PR) + Very Good Partial Response (VGPR) + Near Complete Response (nCR) + Stringent Complete Response (sCR) + Complete Response (CR)
  • Percentage of patients achieving at least very good partial response rate (VGPR+nCR+sCR+CR) [ Time Frame: Day +100 ] [ Designated as safety issue: No ]
  • Toxicity of V-BEAM [ Time Frame: Day +100 ] [ Designated as safety issue: Yes ]
  • Time to neutrophil engraftment after V-BEAM. [ Time Frame: Day +100 ] [ Designated as safety issue: Yes ]
    Time to neutrophil engraftment is defined as duration between Day 0 to the first day of ANC > 0.5x109/L post transplant when it is sustained for more than three consecutive days.
  • Overall survival (OS) [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • Treatment related mortality (TRM) of V-BEAM [ Time Frame: Day +100 ] [ Designated as safety issue: Yes ]
  • Time to platelet engraftment after V-BEAM. [ Time Frame: Day +100 ] [ Designated as safety issue: Yes ]
    Time to platelet engraftment is defined as the duration between Day 0 to the first day of platelet count sustained at > 20x109/L without transfusion. The median time to neutrophil and platelet engraftment will be reported.
Not Provided
Not Provided
 
Phase II Study of V-BEAM Conditioning Regimen Prior to Second Autologous Stem Cell Transplantation
A Phase II Study of V-BEAM (Bortezomib, Carmustine, Etoposide, Cytarabine, and Melphalan) as Conditioning Regimen Prior to Second Autologous Stem Cell Transplantation for Multiple Myeloma

BEAM regimen (BCNU, etoposide, cytarabine, and melphalan) is the most commonly used conditioning regimen for relapsed/refractory lymphoma patients needing autologous stem cell transplantation. Since these components are all effective in myeloma and bortezomib has shown promising results in the transplant setting, here the investigators propose a phase II study to investigate the combination of bortezomib and BEAM as a new conditioning regimen for patients who relapse or progress after the first autologous transplantation and for whom a second autologous transplant is considered.

Not Provided
Interventional
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Multiple Myeloma
  • Drug: Bortezomib
    Other Name: Velcade
  • Drug: Carmustine
    Other Name: BCNU, BiCNU®
  • Drug: Etoposide
    Other Name: Vepesid, VP-16
  • Drug: Cytarabine
    Other Name: Ara-C, Cytosar-U, 1-β-Arabinofuranosylcytosine, Arabinosylcytosine, Cytosine arabinoside
  • Drug: Melphalan
    Other Name: Alkeran®, L-PAM
  • Procedure: Stem cell infusion
Experimental: V-BEAM + Stem Cell Infusion
Bortezomib IV or SC (1.3mg/m2) on Days -6, -3, +1 and +4 Carmustine IV (300mg/m2) on Day -7 Etoposide IV twice daily (100 mg/m2) on Days -6, -5, -4, and -3 Cytarabine IV twice daily (100 mg/m2) on Days -6, -5, -4, and -3 Melphalan IV (140 mg/m2) on Day-2 Stem cell infusion on Day 0
Interventions:
  • Drug: Bortezomib
  • Drug: Carmustine
  • Drug: Etoposide
  • Drug: Cytarabine
  • Drug: Melphalan
  • Procedure: Stem cell infusion
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
10
December 2013
August 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patient must have a histologically confirmed diagnosis of multiple myeloma.
  • Patient must have received a prior autologous stem cell transplantation with melphalan conditioning for multiple myeloma with subsequent disease progression and repeat autologous stem cell transplantation is deemed appropriate by the treating physicians.
  • Patient must receive induction chemotherapy including 2 to 4 cycles of anti-myeloma therapy including bortezomib, with or without immune modulating agents and/or corticosteroids, Completion of induction therapy will occur within 30 days of first study drug dose.
  • Patient must have ≥ 2x106/kg CD34+ autologous stem cells available for transplantation.
  • Patient must be ≥ 18 years of age.
  • Patient must have life expectancy of greater than 6 months.
  • Patient must have an ECOG performance status ≤ 2 or Karnofsky performance status ≥ 60% (see Appendices A and B)
  • Patient must have normal bone marrow and organ function as defined below within 14 days prior to first study drug dose (conditioning regimen):

    • Absolute neutrophil count ≥500/mm3
    • Platelets ≥ 50,000/mm3
    • Hemoglobin ≥ 8 g/dl
    • Total bilirubin ≤ 1.5 x IULN
    • AST(SGOT)/ALT(SGPT) ≤ 3.0 x IULN
    • Creatinine clearance (Appendix C) ≥30 mL/min/1.73m2
  • Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry through Day +100 visit. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.
  • Patient must be able to understand and willing to sign an IRB approved written informed consent document.

Exclusion Criteria:

  • Patient must not be refractory to induction therapy. Refractory is defined as disease progression while on therapy or within 30 days following completion of therapy.
  • Patient must not have had disease progression requiring active treatment within 12 months of previous autologous stem cell transplant. Maintenance therapy is not considered active treatment.
  • Patient must not have peripheral neuropathy ≥ grade 3 based on NCI CTCAE v 4.0 (Appendix D).
  • Patient must not be receiving renal replacement therapy, hemodialysis, or peritoneal dialysis.
  • Patient must not have another concurrent malignancy requiring treatment.
  • Patient must not be receiving any other investigational agents within 14 days prior to the first dose of study drug.
  • Patient must not have known brain metastases. Patients with known brain metastases must be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.
  • Patient must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to bortezomib, carmustine, etoposide, cytarabine, and melphalan, or other agents used in the study.
  • Patient must not have an uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Patient must not be pregnant and/or breastfeeding.

Inclusion of Women and Minorities

-Both men and women and members of all races and ethnic groups are eligible for this trial.

Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01653418
201208046
No
Washington University School of Medicine
Washington University School of Medicine
Not Provided
Principal Investigator: Ravi Vij, M.D. Washington University School of Medicine
Washington University School of Medicine
January 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP